Nurse practitioner commentary frames microdosing as an access and trust problem

A commentary published May 26, 2026, in the Journal of the American Association of Nurse Practitioners argues that patient microdosing of GLP-1 drugs and use of illicit "research-grade" peptides persist not mainly because of shortages, but because of cost and provider stigma ^[1][2].

The piece notes that the FDA has resolved the semaglutide and tirzepatide shortages that once allowed mass compounding, changing the regulatory picture for compounded obesity drugs ^[1][2]. Even so, the author writes that "ongoing affordability barriers continue to drive patient desperation" toward do-it-yourself dosing strategies and purchases from "online sources and unregulated providers including medical spas," despite recent federal pricing agreements meant to lower GLP-1 costs ^[1][2].

The commentary identifies two main reasons patients deliberately take doses lower than what is prescribed, a practice it calls "microdosing": gastrointestinal tolerability, meaning patients want to avoid nausea and other stomach side effects, and what the author calls "vanity weight" goals, or a desire to lose a smaller amount of weight than a full clinical dose is meant to treat ^[1][2]. The commentary is framed as a brief report meant to fill gaps for nurse practitioners on the specific side effects and dosing errors tied to these practices, along with safety risks from pen manipulation, use of compounded vials, and sharing medication between patients ^[1][2].

The author also points to provider weight bias as a reason some patients avoid raising the topic of microdosing or illicit peptides with a clinician in the first place, instead seeking unregulated alternatives on their own ^[1][2]. The commentary offers what it describes as practical strategies for nurse practitioners to reduce stigma during patient visits, and argues that as the regulatory window for mass compounding closes, NPs need ways to guide patients away from what the piece calls "hazardous false economies" and to manage patients already using compounded products ^[1][2]. The commentary also says there remains a narrow, legitimate role for compounding in patients with documented allergies to approved products ^[1][2]. It further flags legal pitfalls around compounded drug "copies" ^[1][2].

Why it matters for patients

For patients currently paying out of pocket for Ozempic, Wegovy, Mounjaro, or Zepbound, this commentary describes a pattern where cost pressure and discomfort with side effects lead some people to take less medication than prescribed, or to seek products from sources outside the regulated pharmacy supply chain ^[1][2]. The author's framing suggests this is not simply a leftover habit from the shortage era; it says federal pricing agreements have not fully solved the affordability problem for everyone ^[1][2].

The commentary's point about weight bias is also notable for patients: it suggests some people don't feel comfortable telling a nurse practitioner or other clinician that they are microdosing or buying peptides online, which the author frames as a communication gap that leaves patients managing safety risks, such as pen manipulation or use of compounded vials, without clinical guidance ^[1][2].

The sources here are a single-author commentary and its abstract listing, not a study with new data on how many patients microdose or how often safety problems occur ^[1][2]. The commentary does not name specific pricing agreements, name which peptides are most implicated, or quantify how common microdosing is among GLP-1 users; those figures are not given in the available text ^[1][2].

What happens next

The commentary states that regulatory conditions are changing as the FDA-recognized shortages that allowed broad compounding have ended, which it says narrows the legal basis for mass compounding of semaglutide and tirzepatide going forward ^[1][2]. Beyond that general shift, the source material does not specify further dated actions, agency decisions, or upcoming reviews tied to this commentary.